Procter & Gamble Q1 Forecast Cut As Global Challenges Persist, Goldman Sachs Warns Goldman Sachs analyst Bonnie Herzog lowered Procter & Gamble Company’s (NYSE:PG) first-quarter estimates to reflect softer end markets. Consequently, the analyst cut the price target to $164 (from $165), with a Neutral rating. The analyst writes that while scanner trends show resilience for the company and continued growth in the U.S., challenges in international markets like the Middle East and China may offset this. The analyst anticipates no recovery for SK-II until late 2024, when negative sentiment toward Japanese brands begins to ease. Herzog is lowering first-quarter estimates, expecting organic sales growth of around 2%, which is expected to be mostly neutralized by FX translation headwinds, leading to flat net sales growth for the quarter. Moreover, the analyst anticipates slight gross margin expansion supporting 4.7% year-over-year EPS growth to $1.91, down from $1.96 earlier. The analyst says that due to challenges in Procter & Gamble’s end markets and a slowdown to 2% growth in fourth-quarter, investor expectations have shifted to the lower end of PG’s FY25 organic sales growth guidance of 3%-5% (vs. GS/consensus estimates of 3.5% and 3.6%). Coupled with productivity gains, this should yield over 5% EPS CAGR from FY24 to FY27, slightly below the previous 6.5% CAGR, adds the analyst. Overall, the analyst remains cautious about the stock, especially as PG's organic sales growth has decelerated over the past few quarters while trading at elevated multiples. Investors can gain exposure to the stock via iShares U.S. Consumer Staples ETF (NYSE:IYK) and Vanguard Consumer Staples ETF (NYSE:VDC) Price Action: PG shares are down 0.93% at $167.31 at the last check Monday. Image from Shutterstock Read Next: Metals in Tampons: FDA Initiates New Safety Measures and Testing Latest Ratings for PG Date Firm Action From To Jan 2022 RBC Capital Maintains Sector Perform Jan 2022 Deutsche Bank Maintains Buy Jan 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings for PG View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? PROCTER & GAMBLE (PG): Free Stock Analysis Report This article Procter & Gamble Q1 Forecast Cut As Global Challenges Persist, Goldman Sachs Warns originally appeared on Benzinga.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Procter & Gamble Q1 Forecast Cut As Global Challenges Persist, Goldman Sachs Warns
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...